Federal health advisers are weighing the first-of-a-kind approval of MDMA, the mind-altering club drug, as a treatment for PTSD
The Food and Drug Administration convened a panel of outside experts Tuesday to review the latest research on the drug, — part of a decadeslong effort by psychedelic advocates to win medical acceptance for the drug's purported benefits.convened a panel of outside experts Tuesday to review the latest research on the drug, which appears to show it can help relieve post-traumatic stress disorder when combined with talk therapy.
“This application is both consequential and complex,” FDA reviewer Dr. Tiffany R. Farchione said at the beginning of Tuesday's meeting. The FDA will ask its outside panel about that issue and several others, including uncertainty about how long the benefits of MDMA might last. About 25% of patients dropped out of a follow-up study designed to track long-term outcomes.
Representatives for drugmaker Lykos Therapeutics said Tuesday they agreed with such precautions and hoped that would hasten the drug's approval.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationFederal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD. Advisers to the Food and Drug Administration are scheduled to vote on the drug's safety and effectiveness Tuesday afternoon. It potentially sets the stage for federal approval later this year.
Read more »
Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationFederal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD.
Read more »
Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationFederal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD.
Read more »
Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationFederal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD
Read more »
Psychedelic drug MDMA faces FDA panel in bid to become first-of-a-kind PTSD medicationFederal health advisers are considering the first request to approve the mind-altering club drug MDMA as a treatment for PTSD.
Read more »
FDA panel to evaluate psychedelic MDMA for treatment of PTSD for first timeThe U.S. Food and Drug Administration held a meeting to discuss a therapy based on the psychedelic drug MDMA for patients with post-traumatic stress disorder for the first time.
Read more »